- Home
- PHAT vs CAC Comparison
PHAT vs CAC Comparison
Compare PHAT & CAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PHAT | CAC |
|---|---|---|
| Founded | 2018 | 1875 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 894.0M | 857.1M |
| IPO Year | 2019 | 1996 |
Fundamental Metrics
Financial Performance| Metric | PHAT | CAC |
|---|---|---|
| Price | $12.58 | $47.62 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 2 |
| Target Price | $19.83 | ★ $47.00 |
| AVG Volume (30 Days) | ★ 1.3M | 76.7K |
| Earning Date | 04-30-2026 | 04-28-2026 |
| Dividend Yield | N/A | ★ 3.51% |
| EPS Growth | ★ 42.72 | 6.08 |
| EPS | N/A | ★ 1.29 |
| Revenue | ★ $175,110,000.00 | $41,739,000.00 |
| Revenue This Year | $93.04 | $19.15 |
| Revenue Next Year | $58.91 | $6.05 |
| P/E Ratio | ★ N/A | $37.22 |
| Revenue Growth | ★ 216.93 | 16.96 |
| 52 Week Low | $3.69 | $35.00 |
| 52 Week High | $18.31 | $53.71 |
Technical Indicators
Market Signals| Indicator | PHAT | CAC |
|---|---|---|
| Relative Strength Index (RSI) | 53.61 | 42.49 |
| Support Level | $10.38 | $47.25 |
| Resistance Level | $13.03 | $51.57 |
| Average True Range (ATR) | 0.94 | 1.46 |
| MACD | 0.00 | -0.25 |
| Stochastic Oscillator | 85.91 | 4.55 |
Price Performance
Historical ComparisonAbout PHAT Phathom Pharmaceuticals Inc.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.
About CAC Camden National Corporation
Camden National Corporation is a banking solutions provider in the United States. Its core business is providing commercial banking products to individuals and corporates. Its consumer and commercial banking services entail services such as loans and deposits, savings and online banking, treasury management solutions and non-profit products to consumer, institutional, municipal, non-profit and commercial customers. The company also offers investment management and fiduciary services.